Skip to main content
Erschienen in: Tumor Biology 7/2016

12.01.2016 | Original Article

Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation

verfasst von: Qing-Qi Ren, Shun-Jun Fu, Qiang Zhao, Zhi-Yong Guo, Fei Ji, Mao-Gen Chen, Lin-Wei Wu, Xiao-Shun He

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Prognostic value of peripheral monocyte, as a member of inflammatory cells, was widely being investigated. The aim of this study was to evaluate the prognostic value of preoperative peripheral blood monocyte count for hepatocellular carcinoma (HCC) patients who underwent liver transplantation (LT) and the relationship between monocyte count and tumor-related characteristics. We retrospectively analyzed the clinical data of 101 HCC patients after LT. Preoperative monocyte count and demographic, clinical, and pathologic data were analyzed. The optimal cutoff value of monocyte count was 456/mm3, with the sensitivity and specificity of 69.4 and 61.5 %, respectively. Elevated preoperative peripheral blood monocyte count was significantly associated with large tumor size. The 1-, 3-, and 5-year disease-free survival (DFS) (80.9, 70.1, and 53.3 % vs 55.1, 38.7, and 38.7 %, P = 0.007) and overall survival (OS) rates (95.7, 76.6, and 64.8 % vs 72.2, 44.1, and 36.1 %, P = 0.002) of HCC patients in the peripheral blood monocyte count ≤456/mm3 group were higher than those in the peripheral blood monocyte count >456/mm3 group. In conclusion, elevated preoperative peripheral blood monocyte count was significantly associated with advanced tumor stage and it can be considered as a prognostic factor for HCC patients after LT.
Literatur
1.
2.
Zurück zum Zitat Zhang TT, Zhao XQ, Liu Z, Mao ZY, Bai L. Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients. Clin Transl Oncol. 2015. Zhang TT, Zhao XQ, Liu Z, Mao ZY, Bai L. Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients. Clin Transl Oncol. 2015.
3.
Zurück zum Zitat Zhou YM, Zhang XF, Li B, Sui CJ, Yang JM. Postoperative complications affect early recurrence of hepatocellular carcinoma after curative resection. BMC Cancer. 2015;15:689.CrossRefPubMedPubMedCentral Zhou YM, Zhang XF, Li B, Sui CJ, Yang JM. Postoperative complications affect early recurrence of hepatocellular carcinoma after curative resection. BMC Cancer. 2015;15:689.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Zhou D, Zhang Y, Xu L, Zhou Z, Huang J, Chen M. A monocyte/granulocyte to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma. Sci Rep. 2015;5:15263.CrossRefPubMedPubMedCentral Zhou D, Zhang Y, Xu L, Zhou Z, Huang J, Chen M. A monocyte/granulocyte to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma. Sci Rep. 2015;5:15263.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Lin ZX, Ruan DY, Li Y, Wu DH, Ma XK, Chen J, et al. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection. World J Gastroenterol. 2015;21(38):10898–906.CrossRefPubMedPubMedCentral Lin ZX, Ruan DY, Li Y, Wu DH, Ma XK, Chen J, et al. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection. World J Gastroenterol. 2015;21(38):10898–906.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Shen SL, Fu SJ, Huang XQ, Chen B, Kuang M, Li SQ, et al. Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection. BMC Cancer. 2014;14:744.CrossRefPubMedPubMedCentral Shen SL, Fu SJ, Huang XQ, Chen B, Kuang M, Li SQ, et al. Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection. BMC Cancer. 2014;14:744.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Lee SD, Kim SH, Kim YK, Lee SA, Park SJ. Prognostic significance of preoperative peripheral blood monocyte ratio in patients with hepatocellular carcinoma. World J Surg. 2014;38:2377–85.CrossRefPubMed Lee SD, Kim SH, Kim YK, Lee SA, Park SJ. Prognostic significance of preoperative peripheral blood monocyte ratio in patients with hepatocellular carcinoma. World J Surg. 2014;38:2377–85.CrossRefPubMed
8.
Zurück zum Zitat Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57:1013–20.CrossRefPubMed Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57:1013–20.CrossRefPubMed
9.
Zurück zum Zitat Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31:883.CrossRefPubMed Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31:883.CrossRefPubMed
10.
Zurück zum Zitat Parisi I, Tsochatzis E, Wijewantha H, Rodríguez-Perálvarez M, De Luca L, Manousou P, et al. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl. 2014;20:1327–35.CrossRefPubMed Parisi I, Tsochatzis E, Wijewantha H, Rodríguez-Perálvarez M, De Luca L, Manousou P, et al. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl. 2014;20:1327–35.CrossRefPubMed
11.
Zurück zum Zitat Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery. 2006;139:755–64.CrossRefPubMed Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery. 2006;139:755–64.CrossRefPubMed
12.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:633–9.CrossRef Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:633–9.CrossRef
13.
Zurück zum Zitat Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.CrossRefPubMed Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.CrossRefPubMed
14.
Zurück zum Zitat Zheng SS, Xu W, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726–32.CrossRefPubMed Zheng SS, Xu W, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726–32.CrossRefPubMed
15.
Zurück zum Zitat Han M, Guo ZY, Zhao Q, Wang XP, Yuan XP, Jiao XY, et al. Liver transplantation using organs from deceased organ donors: a single organ transplant center experience. Hepatobiliary Pancreat Dis Int. 2014;13:409–15.CrossRefPubMed Han M, Guo ZY, Zhao Q, Wang XP, Yuan XP, Jiao XY, et al. Liver transplantation using organs from deceased organ donors: a single organ transplant center experience. Hepatobiliary Pancreat Dis Int. 2014;13:409–15.CrossRefPubMed
16.
Zurück zum Zitat Chai EZ, Siveen KS, Shanmugam MK, Arfuso F, Sethi G. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem J. 2015;468:1–15.CrossRefPubMed Chai EZ, Siveen KS, Shanmugam MK, Arfuso F, Sethi G. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem J. 2015;468:1–15.CrossRefPubMed
17.
Zurück zum Zitat Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell AL, et al. Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol. 2014;49:116–39.CrossRefPubMedPubMedCentral Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell AL, et al. Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol. 2014;49:116–39.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res. 2014;74:8–14.CrossRefPubMed Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res. 2014;74:8–14.CrossRefPubMed
19.
Zurück zum Zitat Hung RJ, Ulrich CM, Goode EL, Brhane Y, Muir K, Chan AT, et al. Cross cancer genomic investigation of inflammation pathway for five common cancers: lung, ovary, prostate, breast, and colorectal cancer. J Natl Cancer Inst. 2015. doi:10.1093/jnci/djv246. Hung RJ, Ulrich CM, Goode EL, Brhane Y, Muir K, Chan AT, et al. Cross cancer genomic investigation of inflammation pathway for five common cancers: lung, ovary, prostate, breast, and colorectal cancer. J Natl Cancer Inst. 2015. doi:10.​1093/​jnci/​djv246.
20.
21.
22.
Zurück zum Zitat Posner LJ, Miligkos T, Gilles JA, Carnes DL, Taddeo DR, Graves DT. Monocyte chemoattractant protein-1 induces monocyte recruitment that is associated with an increase in numbers of osteoblasts. Bone. 1997;21:321–7.CrossRefPubMed Posner LJ, Miligkos T, Gilles JA, Carnes DL, Taddeo DR, Graves DT. Monocyte chemoattractant protein-1 induces monocyte recruitment that is associated with an increase in numbers of osteoblasts. Bone. 1997;21:321–7.CrossRefPubMed
23.
Zurück zum Zitat Craig MJ, Loberg RD. CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev. 2006;25:611–9.CrossRefPubMed Craig MJ, Loberg RD. CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev. 2006;25:611–9.CrossRefPubMed
25.
Zurück zum Zitat Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM, Wang D, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology. 2013;57:1107–16.CrossRefPubMed Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM, Wang D, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology. 2013;57:1107–16.CrossRefPubMed
26.
Zurück zum Zitat Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, et al. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology. 2015;62:481–95.CrossRefPubMedPubMedCentral Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, et al. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology. 2015;62:481–95.CrossRefPubMedPubMedCentral
Metadaten
Titel
Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation
verfasst von
Qing-Qi Ren
Shun-Jun Fu
Qiang Zhao
Zhi-Yong Guo
Fei Ji
Mao-Gen Chen
Lin-Wei Wu
Xiao-Shun He
Publikationsdatum
12.01.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4758-3

Weitere Artikel der Ausgabe 7/2016

Tumor Biology 7/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.